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Conjugation of a novel histidine derivative to biomolecules and
labelling with [99mTc(OH2)3(CO)3]+
Abstract
The new histidine derivative
3-[1-[3-(9H-fluoren-9-ylmethoxycarbonylamino)-propyl]-1H-imidazol-4-yl]-2-(3-trimethylsilanyl-ethyl
carboxyamino)-propionic acid methyl ester (7) has been prepared via alkylation of the histidine urea
derivative (7S)-5,6,7,8-tetrahydro-7-(methoxycarbonyl)-5-oxoimidazo-[1,5-c]-pyrimidine (2) with
Fmoc-protected 3-iodopropyl-amine, followed by ring opening with 2-trimethylsilylethanol. After Fmoc
cleavage by HNEt2, the histidine amine derivative was coupled to biotin, to the pentapeptide
leucine-enkephalin and to Vitamin B12-b-acid by amide formation, employing TBTU as the coupling
reagent. In order to make the histidine accessible for labelling, the teoc protecting group was removed
by either NBu4F (for the biotin conjugate) or by TFA (for the enkephalin and B12 conjugates). Reaction
of a 10(-4) M solution of the bioconjugates with [99mTc(H2O)3(CO)3]+ at 50 degrees C for 30 min led
to the formation of one single new peak in the HPLC radiochromatogram in each case, confirming
quantitative labelling of the respective biomolecules. To assess the nature of the labelled compounds,
the rhenium analogues with Re(CO)3 were also synthesised and similar retention times confirmed the
identity with the 99mTc labelled conjugates.
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The new histidine derivative 3-{1-[3-(9H-fluoren-9-ylmethoxycarbonylamino)-propyl]-1H-imidazol-4-yl}-2-(3-
trimethylsilanyl-ethylcarboxyamino)-propionic acid methyl ester (7) has been prepared via alkylation of the histidine 
urea derivative (7S )-5,6,7,8-tetrahydro-7-(methoxycarbonyl)-5-oxoimidazo-[1,5-c]-pyrimidine (2) with Fmoc-protected 
3-iodopropyl-amine, followed by ring opening with 2-trimethylsilylethanol. After Fmoc cleavage by HNEt2, the 
histidine amine derivative was coupled to biotin, to the pentapeptide leucine-enkephalin and to Vitamin B12-b-acid by 
amide formation, employing TBTU as the coupling reagent. In order to make the histidine accessible for labelling, the 
teoc protecting group was removed by either NBu4F (for the biotin conjugate) or by TFA (for the enkephalin and B12 
conjugates). Reaction of a 10−4 M solution of the bioconjugates with [99mTc(H2O)3(CO)3]+ at 50 °C for 30 min led to the 
formation of one single new peak in the HPLC radiochromatogram in each case, confirming quantitative labelling of the 
respective biomolecules. To assess the nature of the labelled compounds, the rhenium analogues with Re(CO)3 were also 
synthesised and similar retention times confirmed the identity with the 99mTc labelled conjugates.
Introduction
The labelling of biologically active molecules with 99mTc is a field 
of intense research,1–4 as 99mTc is one of the most widely employed 
isotopes for imaging in nuclear medicine. This is due to the favour-
able properties of this isotope: the emission of a 140 keV -ray 
with an abundance of 89% and a half-life of 6.02 h. In the past 
compounds with 99mTc in an almost exclusively +V oxidation state 
have been used for labelling purposes but recently the 99mTc(CO)3+ 
core in which the oxidation state is +1 has attracted much attention. 
Three reasons account for this interest: 1) the robustness of com-
plexes with this core, 2) the high affinity of the Tc(I) ion to a large 
variety of donor atoms and 3) the easy preparation of the precursor 
[99mTc(H2O)3(CO)3]+. In fact, GMP produced kits for preparing 
[99mTc(H2O)3(CO)3]+ are now commercially available (Isolink from 
Malinckrodt, Inc.), which is expected to furnish the way towards 
commercial applications.5
To avoid dissociation of the metal ion from the bioconjugate in 
biological systems, the ligand covalently attached to the biomol-
ecule should bind as tight as possible to the “fac-[99mTc(CO)3]+” 
moiety. On the basis of thermodynamic considerations a tridentate 
ligand is preferred. It forms highly robust complexes and also pre-
vents cross-metalation to ligands present in blood plasma, in partic-
ular to those with sulfur or aromatic nitrogen donors. A 99mTc(CO)3 
complex with a tridentate ligand is less prone to undergo such a 
undesired reaction due to its coordinative saturatation and because 
thermodynamic factors strongly disfavour the dissociation of one 
donor atom from the tridentate ligand.
It is often important for the biological activity of a labelled 
compound that the overall charge does not change, hence a mono-
anionic tridentate ligand is required for the fac-[99mTc(CO)3]+ core. 
Systematic investigations about the in vitro and in vivo properties 
of a variety of complexes containing the Tc(CO)3 and Re(CO)3 
groups6,7 showed that histidine in particular forms complexes 
of high (biological) stability.8–10 Furthermore, histidine is very 
attractive for labelling with [99mTc(H2O)3(CO)3]+, since short 
reaction times (30 min) at relatively low temperatures (50 °C) and 
ligand concentration result in quantitative labelling yield, making it 
ideally suited for radiopharmaceutical applications. Another virtue 
of the histidine ligand is its chirality, which implies that the formed 
Tc(His–N–R)(CO)3 complex moiety will be enantiomerically pure 
if enantiomerically pure histidine is used.
In contrast, other favourable mono-anionic ligands with a NNO 
donor set such as the pama-ligand ([pyridine-2-ylmethyl)-amino]-
acetic acid) will always lead to a racemic complex.11 In combi-
nation with chiral biomolecules, mixtures of diastereomers will 
result, which should be avoided for pharmaceutical applications 
in particular.
The favourable coordination properties of histidine to the 
different organometallic Mo(-allyl)(CO)2 core, and the facile 
derivatisation of Mo(His)(-allyl)(CO)2 by alkylation of the im-
idazole N-atom have been previously reported by van Staveren 
and Metzler-Nolte in a series of papers.12–15 In addition it was 
shown that the Mo(-allyl)(CO)2 complex can be attached to the 
N-terminus of a peptide as a last step of a solid phase synthesis 
protocol.14
Recently we reported the carboxylic acid histidine derivative 
methyl 1-(2-tert-butoxy-2-oxoethyl)-N-(9H-fluoren-9-ylmethox
ycarbonyl)histidinate (1) which was coupled to the amino group 
of phenylalanine by employing standard peptide chemistry meth-
ods.16 After deprotection histidine served as an efficient ligand 
for 99mTc(CO)3. Since it is often desired to attach the bifunctional 
chelator to the C-terminus of e.g. a peptide we extend this study 
by introducing an amino group for coupling to the carboxylate 
of biomolecules. We report in the present work the synthesis of 
a protected histidine derivative with an amino group attached on 
an alkyl chain to the N-atom (7). Although seemingly straight-
forward, the introduction of such a linking group is not routine 
due to the reactivity of the histidine precursor. The -amine pro-
tecting group can be removed either under acidic or Lewis basic 
conditions which is important in case of sensitive biomolecules. To 
exemplify the versatility of this approach we show the convenient 
coupling of this compound to vitamin B12, enkephalin and biotin, 
biomolecules of varying complexity. Furthermore, we demonstrate 
that the derivatised biomolecules can be efficiently labelled with 
[99mTc(OH2)3(CO)3]+ under mild conditions.
† Electronic supplementary information (ESI) available: complete 1H and 
13C NMR spectra of 14, 15, 16 and 19. See http://www.rsc.org/suppdata/ob/
b4/b405575f/
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and to elucidate the X-ray structure. An ORTEP presentation is 
given in Fig. 1, confirming the molecular structure of the ligand.
During the reaction or column-chromatographic purification over 
silica elimination of CO2 and formation of a benzyl-cation (or tropy-
lium ion) occurred. This cation presumably reacts with the N-atom 
to form compound 5. The benzyl group is known to have a prefer-
ence for the His-N atom and, in fact, this benzyl moiety is a com-
mon protecting group for the N of His in peptide chemistry.17–19
To circumvent the CBz protecting group, we examined other 
N-alkylation reagents with ethyl and propyl spacers and with 
protecting groups compatible with Fmoc deprotection of N. The 
compounds Boc-NHCH2CH2I, Trt-NHCH2CH2I and the propyl deri-
vatives Boc-NH-CH2CH2CH2Br and Trt-NH-CH2CH2CH2I were 
prepared from the corresponding alcohols but all alkylation reac-
Results and discussion
Synthesis
Histidine as a very efficient ligand is the focus of our interest and 
our aim was a derivative with an additional amine group linked by 
an alkyl chain to the N-atom in the imidazole side chain. This amine 
group enables ligand conjugation to a carboxylate in biomolecules. 
The approach is complementary to the one employing 1, but the 
N-terminus of a peptide is usually buried in the core of the protein. 
With the new method, conjugation of histidine to the C-terminus, 
which is usually on the exterior of the protein, is possible.
A general structure of our target compound as well as a retrosyn-
thetic analysis is shown in Scheme 1. The -amine and the amine 
moiety on the alkyl-chain carry orthogonal protecting groups. In 
analogy with the synthesis of 1, we planned alkylation of the N-
atom in the urea-protected derivative 2, yielding a cationic interme-
diate. Subsequent ring opening of the urea moiety with an alcohol 
will then give the desired but still protected compound (Scheme 1). 
Although this synthetic pathway seems straightforward we encoun-
tered a number of unexpected difficulties, which will be discussed 
in brief below.
Originally we envisaged to perform the ring opening of the 
cationic urea derivative with (9H-fluoren-9-yl)-methanol to yield 
an -amine Fmoc protected derivative. Therefore we concentrated 
on alkylation of the N with protected iodo-alkylamines that would 
resist the conditions required for Fmoc cleavage. In the light of 
later biomolecule coupling, a short linker between histidine and 
the biomolecule is preferable and we started with an ethyl spacer. 
The iodide CBz–NH–CH2CH2I (4) was synthesised from the cor-
responding alcohol 3 by using triphenylphosphine, imidazole and 
iodine (see Scheme 2). Subsequently histidine–urea derivative 2 was 
reacted with 4, followed by urea-opening with (9H-fluoren-9-yl)-
methanol. Surprisingly, the compound isolated after work-up was 
not the expected CBz derivative, but compound 5 (see Scheme 2). 
The constitution of the molecule was clearly established from the 
mass spectrum as well as from the 1H and 13C NMR spectroscopic 
data. In addition it was possible to coordinate the ligand to Tc(CO)3 
Scheme 1
Scheme 2
Fig. 1 ORTEP projection of Tc(His-N-benzyl)(CO)3·H2O at 50% prob-
ability level. Hydrogen atoms as well as the H2O molecule are omitted 
for clarity. Selected bond lengths (Å): Tc(1)–C(1) 1.895(6), Tc(1)–C(2) 
1.916(5), Tc(1)–C(3) 1.929(5), Tc(1)–O(4) 2.165(3), Tc(1)–N(1) 2.200(3), 
Tc(1)–N(2) 2.204(3).
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that small amounts of water in combination with reaction tempera-
tures of 70 °C lead to cleavage of the methyl ester. This concerted 
cleavage is ideal because both protecting groups are released in 
the same synthetic step, making the histidine now accessible for 
labelling.
To more generalize the approach we moved on to the attach-
ment of 8 to a receptor-binding peptide. Leucine–Enkephalin, a 
pentapeptide with the sequence H-Tyr-Gly-Gly-Leu-Phe-OH was 
chosen. This pentapeptide was first isolated as a mixture with its 
position 4 methionine analogue by Hughes et al. in 1975 from pig 
brain.21 The presence of this peptide was later also demonstrated in 
various human tissues, such as the human brain, the human spinal 
fluid and in blood plasma. It has an action similar to morphine, exhi-
biting a high affinity for the opioid receptor and acting as a natural 
pain killer.22
The protected derivative Boc-(Tyr-OtBu)-Enk-OH (11) was pre-
pared on a resin with a 2-Cl-trityl linker via standard peptide solid 
phase techniques. The peptide can be cleaved under mildly acidic 
conditions from the resin, leaving the acid sensitive side-chain pro-
tecting groups unaffected. In a next step compound 8 was reacted 
with 11 employing TBTU as the coupling reagent, which furnished 
in a clean reaction the expected conjugate 12 after preparative 
HPLC purification (Scheme 5). The Boc, tert-butyl ether and the 
teoc group were then simultaneously removed in one step by the 
reaction with TFA in CH2Cl2, to afford the fully deprotected peptide 
13 in higher than 97% purity. The HRMS and NMR spectroscopic 
data are consistent with the proposed constitution.
As an example for a more complex and biologically important 
molecule belonging to a different category, we selected vitamin 
B12 or cobalamin. Vitamin B12 is necessary for the proper function 
of the nervous system and for the metabolism of carbohydrates, 
proteins and fat and it is also involved in the reductive conversion 
of ribonucleotides to deoxyribonucleotides to generate DNA.23,24 
Vitamin B12 comprises amides, benzimidazole, phosphate esters 
and other groups which are potentially coordinating for the 
[Tc(CO)3]+ moiety. Strong ligands are required in order to yield one 
well-defined product.
Cobalamin contains five terminal amide groups, but no free 
carboxylate as required for its coupling to the amine in 8. Accord-
ing to a literature procedure aqueous acid hydrolysis of vitamin B12 
yields a mixture of mono and di-acids. The vitamin B12 compound 
in which the b-amide is hydrolyzed represents the main hydrolysis 
product in this reaction (Scheme 6).25–27 The b-acid can be separated 
by means of ion-exchange column chromatography and preparative 
HPLC in approximately 15% yield.
The coupling of the amine histidine derivative 8 with vitamin 
B12-b-acid 14 does not require pure 8. Instead freshly deprotected 
7 was reacted with 14 in a DMSO/DMF mixture with TBTU as the 
coupling reagent. With preparative HPLC the teoc-protected B12-
histidine conjugate 15 (Scheme 6) was conveniently separated from 
the side products that originated from the Fmoc cleavage. These 
tions with 2 were unsuccessful. After heating at reflux for several 
days, no new compounds could be identified.
To increase reactivity, we then switched to iodo-alkyl amines 
protected by an Fmoc group, well aware that this strategy would 
require a different alcohol for ring opening of the cationic urea inter-
mediate in order to ensure orthogonality between the two amine 
protecting groups. The alcohol 2-trimethylsilylethanol fulfils this 
condition ideally since the 2-trimethylsilylethylcarbonyl (teoc) pro-
tecting group is stable under basic conditions and can be cleaved 
both under Lewis basic conditions employing fluoride ions or under 
acidic conditions by using trifluoroacetic acid.20
The iodo derivatives Fmoc-NH-CH2CH2I and Fmoc-NH-
CH2CH2CH2I (6) were prepared from the corresponding primary 
alcohols. Upon reaction of 2 with Fmoc-NH-CH2CH2I, only small 
amounts of a new product could be observed after a reflux period of 
5 days but over 2 weeks 2 decomposed slowly. In contrast, reflux-
ing 6 with 2 already led to the formation of a significant amount of 
a new product after a reflux period of only 24 h. The reaction was 
complete after 4.5 days. Compound 6 represents the only alkylating 
agent giving a clean reaction with 2 and affording the introduction 
of the desired –NH2 group. Subsequent ring opening of the cationic 
urea derivative with 2-trimethylsilylethanol afforded overnight the 
fully protected histidine amine derivative 7 in a 53% yield (two 
steps) as shown in Scheme 3. Cleavage of the Fmoc group in 7 
could be achieved by treatment with HNEt2 in DMF (Scheme 4) and 
pure 8 could be obtained after purification with preparative HPLC. 
Principally, conjugation of 8 to biomolecules can be performed after 
in situ preparation of 8 from 7 but sometimes purification of the 
resulting bioconjugate is complicated by the presence of fulvene 
derivatives from the Fmoc cleavage.
This synthetic approach now allows the preparation of large 
amounts of histidine amine derivative 7 or 8 respectively. The 
next step consisted of the selection of carboxylic acid-containing 
biomolecules interesting for labelling from a radiopharmaceutical 
point of view. To show that histidine can be introduced in a variety 
of biomolecules we selected diverse biomolecules to demonstrate 
the general versatility of the coupling method with the histidine 
derivative. Biotin was chosen since its labelling is of ongoing inter-
est in radiopharmacy, enkephalin since it represents a less known 
biomolecule from the general class of peptides and vitamin B12 as a 
more complex system with integrated potentially coordinating func-
tions. As for biotin, labelled vitamin B12 is also of strong interest 
for cancer diagnosis and therapy in nuclear medicine.
D-(+)-Biotin, also called vitamin H, was conveniently coupled 
to 8 by using TBTU. The purification via an extractive work-up 
proceeded smoothly, affording compound 9 in pure form. Removal 
of the teoc protecting group was achieved by the reaction of 9 with 
NBu4F in THF/DMF. These conditions hydrolyzed also simultane-
ously but unexpectedly the methyl ester and afforded 10 (Scheme 
4) in good yield as derived from the MS and NMR spectroscopic 
data. Since the fluoride ion is a strong Lewis base, it is conceivable 
Scheme 3
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Scheme 4 Reagents and conditions: i) NEt2, DMF, RT, 91%; ii) biotin, TBTU, DMF, RT, 78%; iii) NBu4F, 70 °C, 79%.
Scheme 5 Reagents and conditions: i) 8, DMF, HNEt2, TBTU, RT, 49%; ii) TFA, CH2Cl2, RT, 88%.
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results show that the TBTU coupling procedure is even suitable 
for derivatizing highly functional molecules such as vitamin B12-
b-acid.
To make the histidine moiety accessible for labelling with 
[99mTc(H2O)3(CO)3]+ the teoc protecting group had to be removed. 
The fluoride method, e.g. the reaction with NBu4F or CsF, was not 
successful and stirring of 15 in the presence of either fluoride source 
in DMF at RT decomposed B12, as is obvious from an irreversible 
colour change from red to purple. Quantitative cleavage of the teoc 
group could only be achieved by stirring 15 in a TFA/CH2Cl2 (4/1) 
mixture at 0 °C for 4.5 h. HPLC analysis indicated the clean conver-
sion of 15 to 16 despite the strongly acidic conditions.
Evidence for the proposed constitution of 15 and 16 was obtained 
from the ESI-positive mass spectra by the [M + H]+ peaks at m/z = 
1710.4 for 15 and m/z = 1565.2 for 16. The 1H NMR spectra of 
15 and 16 in non-protic solvents display a very complicated ap-
pearance, depicting many overlapping resonances. The spectra 
are, however, much clearer in protic solvents such as CD3OD and 
D2O, as a result of H/D exchange of the amides. When recorded in 
these solvents, the coupling reaction can be evaluated in the region 
between 6 and 8.5 ppm. This region consists of four singlets and 
one doublet for 14 with an intensity of 1H for each signal. In the 
spectra of 15 and 16, two additional resonances are observed at 
around 6.95 and 7.64 ppm, owing to the imidazole hydrogen atoms. 
For illustration, the corresponding region between 6 and 8.5 ppm of 
the 1H NMR spectra for 14 and 15 is shown in Fig. 2. The complete 
1H and 13C NMR spectra of 14, 15 and 16 are given in the electronic 
supplementary information.†
In addition, the 13C NMR spectra provide clear evidence for the 
formation of 15 and 16. The region between 185 and 100 ppm con-
sists of 22 resonances for compound 14 and five or four additional 
signals are observed in this region for 15 and 16, respectively, owing 
to the amide and imidazole C-atoms. In the region between 100 
and −5 ppm extra signals belonging to the ligand part of the conju-
gates 15 and 16 with respect to 14 can be identified.
Comparison of the NMR spectra of the B12-conjugates with 
those of the starting material, the vitamin B12-b-acid 14, gives clear 
evidence for the formation of the expected species.
Scheme 6 Reagents and conditions: i) 0.1 M HCl, RT, 15%; ii) 8, TBTU, DMF/DMSO, NEt3, RT, 67%; iii) TFA, CH2Cl2, 0 °C, 64%.
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These three different examples of derivatizing biomolecules 
demonstrate the convenience of introducing compound 8 to dif-
ferent biologically active structures. Due to the possibility of de-
protecting the N either by Lewis acids or by Brønsted acids, the 
proper method can be chosen without affecting the authenticity of 
the original molecule.
Labelling. To identify labelled compounds, it is common in 
radiopharmaceutical chemistry to compare the retention time in the 
HPLC radiochromatogram with the UV/Vis trace of the correspond-
ing non-radioactive Re congener. Since 99mTc labelled compounds 
are present in a concentration of about 10−7 M, radiochromatogra-
phy is the only way of characterization. Correspondingly, before 
labelling the bioconjugates with [99mTc(OH2)3(CO)3]+ the “cold” 
Re(CO)3 analogues were synthesized and accurately characterized. 
In particular, our interest concerned the shift in retention times in 
the HPLC chromatograms between the conjugates with and without 
the Re(CO)3 moiety. The Re analogues can principally be prepared 
along two different pathways. The bioconjugates 10, 13 or 16 are 
either simply reacted with [Re(OH2)3(CO)3]+ or the complex with 
the linking moiety is prepared first and then conjugated to the 
corresponding biomolecule. Obviously, the same product should 
be received for both methods. We adapted the former method for 
Re labelling of 13 only, since the latter method lead to a mixture 
of compounds difficult to separate. Correspondingly, the complex 
Re(His-N-(CH2)3-NHBoc)(CO)3 (17) (Scheme 7) was used as the 
starting material for preparation of the Re(His)(CO)3 derivatized 
biotin and vitamin B12 conjugates. Compound 17 was synthe-
sised via a straightforward alkylation of Re(His)(CO)3 with Boc-
NH-CH2CH2CH2-Br in DMF in the presence of solid Cs2CO3. 
This method has been previously reported for the alkylation of 
Mo(His)(allyl)(CO)2 and Re(His)(CO)3.12,13,16 The Boc-protecting 
group was then removed by stirring 17 in a 2/1 CH2Cl2/TFA mixture 
at 0 °C for 1 h. To avoid decomposition, the temperature should not 
exceed 0 °C and removing the solvent in vacuo should be performed 
without external heating.
The biotin-His-Re(CO)3 conjugate (18) was synthesised by 
reacting deprotected 17 with biotin in DMF in the presence of 
TBTU and purified by column chromatography. Accordingly, the 
vitamin B12 conjugate 19 was synthesised and purified by prepara-
tive HPLC. The constitution of 19 was established by the [M + H]+ 
peak at m/z = 1822.1 in the ESI-positive mass spectra, the presence 
of the fac-Re(CO)3 group in the IR spectrum with the CO vibra-
tions at 2020 and 1901 cm−1 and the 13C NMR resonances at 199.0, 
197.6 and 197.3 ppm. Furthermore, the aromatic region of the 1H 
NMR spectrum contains two additional signals with respect to the 
spectrum of 14, which are assigned as the imidazole-1H resonances. 
With respect to the 13C NMR spectrum of 14, the 13C NMR spectrum 
of 19 shows additional signals owing to the carbon atoms of the his-
tidine ligand and N-attached chain. Attempts to isolate the Re(CO)3 
conjugate of the enkephalin derivative 13 were unsuccessful. Upon 
reaction of 13 with (NEt4)2[ReBr3(CO)3] in 1 M NaHCO3 at 60 °C 
for 1 h we observed a new peak with a retention time slightly higher 
than the starting material (see Table 1). The ratio between the new 
peak and the starting material was about 3/1 and unfortunately they 
could not be separated by preparative HPLC.
Subsequently we investigated the labelling efficiency of the 
coupled histidine ligand under various conditions with 99mTc. Model 
reactions with histidine showed that quantitative complex forma-
tion can be achieved at histidine concentrations as low as 10−6 M 
after 30 min at 95 °C. Heating is required to accelerate the reaction 
at such a high dilution. It is characteristic for the thermal stability 
of carbonyl complexes that no decomposition is found even after 
prolonged boiling in phosphate buffer. However, since some bio-
molecules do not thermally resist such conditions, more moderate 
conditions and, correspondingly, reactions at higher concentrations 
or longer time have to be employed.
Labelling of the conjugates 10, 13 and 16 was performed with a 
solution of [99mTc(OH2)3(CO)3]+, prepared as previously reported.28,29 
The concentration of the bioconjugates was chosen as 10−4 M, 
whereas the concentration of [99mTc(OH2)3(CO)3]+ is determined by 
the generator eluate and is typically in the range 10−6–10−7 M depend-
ing on the “age” of the 99Mo/99mTc generator. After 30 min at 50 °C 
[99mTc(OH2)3(CO)3]+ had disappeared completely and the formation 
of one single new peak could be observed in the radiochromatogram. 
The labelling yield was quantitative for all bioconjugates. The reten-
tion times for the native biomolecules, the unlabelled conjugates, 
the “cold” Re(CO)3 conjugates and the 99mTc labelled molecules are 
given in Table 1. The retention times will be discussed below.
It should be emphasized at this point that the efficiency of la-
belling the histidine ligand in its carboxylic acid form (10) and its 
methyl ester form (13 and 16) is comparable. After 30 min at 50 °C 
all three bioconjugates did react completely with the abundant 
[99mTc(OH2)3(CO)3]+ and the difference, if any, might only manifest 
itself at lower reaction times or lower temperatures. Consequently 
for practical purposes the methyl ester form and the carboxylic acid 
form are equally suited for labelling. Probably, hydrolysis of the 
ester is metal mediated. Once the Tc centre is bidentate coordinated, 
the ester is activated towards hydrolysis due to its close proximity 
Fig. 2 Selected parts from the 1H NMR spectra of 14 and 15 in MeOH-d4. 
Resonances marked with an asterisk constitute amide protons that have not 
completely exchanged for D yet.
Table 1 Retention times for the biotin, enkephalin and vitamin B12 conjugates
Biomolecule Retention Conjugate Retention Conjugate with Retention Conjugate with Retention
 time/min  time/min 99mTc(CO)3 time/min Re(CO)3 time/min
D-(+)-Biotin 8.9a 10 4.1a 10-99mTc(CO)3 16.5a 18 14.1a
Enkephalin 16.4a 13 16.1a 13-99mTc(CO)3 19.5a 13-Re(CO)3 18.2a
14 6.7b 16 7.2b 16-99mTc(CO)3 14.0b 19 13.5b
a C8-column, buffer a) 0.1% TFA, standard TFA-labelling gradient (see experimental section). b C8-column, buffer a) NaOAc buffer, standard NaOAc gradient 
(see experimental section).
Scheme 7 Reagents and conditions: i) Br-CH2CH2CH2NHBoc, Cs2CO3, 
DMF, 40 °C, 97%.
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to the metal and the preorientation for tridentate coordination. This 
is an important finding, because: 1) it saves a reaction step in some 
synthetic sequences and 2) it permits the labelling of biomolecules 
that do not withstand strongly alkaline conditions, such as the B12-
conjugate 16.
For the most sterically demanding conjugate, the vitamin B12 
compound 16, we investigated the accessibility of the histidine 
moiety for labelling as well. Steric accessibility of the chelators 
in general in 16 might be a limiting factor in the labelling process. 
Labelling yields with 16 at 10−5 M were therefore compared with 
those for free histidine at the same concentration. Histidine converts 
completely in the complex 99mTc(His)(CO)3 after 30 min at 50 °C 
and the behaviour observed for a 10−5 M solution of 16 was identi-
cal, complete conversion after a period of 30 min at 50 °C. These 
results demonstrate that histidine attached to the bulky vitamin B12 
is not significantly different in its reactivity than free histidine.
The chromatographic behaviour of unlabelled and 99mTc or Re-
labelled conjugates as shown in Table 1 represents important infor-
mation about hydro-/lipophilicity of biologically active compounds. 
The comparable retention times of “cold” Re(CO)3 and 99mTc(CO)3 
derivatives confirm the identity of the compounds. The differences 
between Re(CO)3 and 99mTc(CO)3 derivatives are explained by the 
separation of the UV/Vis and the radiodetector. It is common to all 
three labelled compounds that their retention times are larger than 
those of the native molecules. Unless the overall charge is changed, 
this is a common feature observed in labelling and not related to the 
fac-[99mTc(CO)3]+ moiety alone. It indicates increased lipophilicity 
which is distinct in case of biotin (8.9 vs. 16.5 min) and less signifi-
cant in case of enkephalin and vitamin B12. Since molecular size 
is also relevant to understanding the delayed retention times and 
biotin is small in comparison to enkephalin and vitamin B12, the 
delay should not exclusively be interpreted in terms of lipophilicity. 
We emphasize that labelled and unlabelled enkephalin and vitamin 
B12 are not very different and that their in vivo behaviour should 
therefore be similar.
Conclusion
Histidine represent an important ligand for the labelling of biomol-
ecules with the [99mTc(CO)3]+ moiety. Its introduction as a tripodal 
ligand causes difficulties due to the various functional groups 
present in the basic structure. We have demonstrated that the 
new N-functionalised fully protected L-histidine derivative 7 can 
conveniently be prepared and, after Fmoc deprotection, easily and 
quantitatively coupled to carboxylate groups in a variety of different 
types of biomolecules. Since the biomolecules stem from peptides 
and vitamins, we emphasize that the method can be generalized to 
other biomolecules as well. After deprotection of N, the biomol-
ecule comprises a highly potent tridentate ligand that can quantita-
tively be labelled with [99mTc(OH2)3(CO)3]+ under mild conditions 
(10−4 M–10−5 M bioconjugate, 50 °C, 30 min). Importantly, there is 
no difference between labelling the free carboxylic acid form (10) 
and the methyl ester form (13 and 16) of histidine and, thus, the 
ligand and the procedure is also versatile for labelling thermally 
and base-sensitive biomolecules such as vitamin B12. One and only 
one product was observed, demonstrating the potency of this ligand 
since the biomolecule of each of the conjugates contains potentially 
coordinating donor atoms
The methods presented herein for conjugation of 8 and sub-
sequent labelling with [99mTc(OH2)3(CO)3]+ are currently being 
extrapolated to other biomolecules. The amine derivative 8 and the 
previously reported carboxylic acid derivative 1 constitute a com-
plementary pair of histidine derivatives. With these, biomolecules 
can be derivatised at either a carboxylic acid or an amine moiety. 
Currently we are investigating the biological in vivo properties of 
the labelled derivatives presented herein.
Experimental
IR spectra were recorded on a Bio-Rad FTS-45 spectrometer with 
the samples in compressed KBr pills. Electrospray ionisation mass 
spectra (ESI-MS) were recorded on a Merck Hitachi M-8000 spec-
trometer in the positive ion mode using methanol as the solvent. 
Fast Atom Bombardment (FAB, nitrobenzylalcohol as matrix)) 
mass spectra, both at low and high resolution, were recorded on a 
Jeol JMS-700 mass spectrometer. As reference compounds for the 
high resolution FAB mass spectra PEG’s of a suitable mass were 
used. For the Re compounds, only the values of the 187Re isotope 
are reported in the low resolution mass spectra, whereas in high 
resolution mass spectra peaks originating from both the 185Re iso-
tope and the 187Re isotope are reported. Elemental analyses were 
performed on a Leco CHNS-932 elemental analyzer. 1H, 13C and 
31P NMR spectra were recorded on a Varian Gemini-2000 (1H at 
300.08 MHz), a Bruker 360 MHz (1H at 360.13 MHz) and a Bruker 
DRX-500 (1H at 500.25 MHz) spectrometer. 1H and 13C NMR spec-
tra were referenced to TMS, using the 13C or residual protio signals 
of the deuterated solvents as internal standards. 31P NMR spectra 
were referenced against 0.1 M H3PO4 in H2O.
HPLC analyses were performed on a Merck-Hitachi L-7000 sys-
tem equipped with a EG&G Berthold LB 508 radiometric detector, 
using Waters XTerra RP8 columns (5 m particle size, 1 × 100 mm) 
and a flow rate of either 0.5 ml min−1 or 1 ml min−1. Chromatograms 
were recorded at 220, 250 and 360 nm. Sodium acetate buffer a) 
was prepared by mixing 2.9 ml acetic acid and 4.55 ml sodium 
hydroxide 2 M in 900 ml water and 100 ml methanol. Tris buffer 
a) was prepared by dissolving tris(hydroxymethyl)aminomethane 
(6.05 g) in water, adding HCl 2 M to reach a pH of 8.2, adjusting 
the volume to 1000 ml, and adding acetonitrile (10 ml). TFA buffer 
a) was prepared by dissolving 1.0 ml of CF3COOH in 1000 ml of 
water. Buffer b) was always methanol. Preparative HPLC separa-
tions were performed on a Varian Prostar system equipped with 
two Prostar 215 pumps and a Prostar 320 UV/Vis detector, using a 
Waters XTerra Prep RP8 column (5 m particle size, 30 × 100 mm) 
or a Macherey-Nagel Nucleosil C-18ec column (7 m particle size, 
100 Å pore size, 40 × 250 mm). Flow rates were 30 ml min−1 for the 
RP8 30 × 100 mm column and 40 ml min−1 for the C-18ec column. 
After the preparative HPLC purification, cobalamin derivatives 
were desalted by applying an aqueous solution of the compound 
to a Chromafix RP18ce cartridge, followed by thoroughly rinsing 
with water. The desalted product was then eluted with methanol, the 
solvent was removed in vacuo, and the product was dried under high 
vacuum. The biotin and enkephalin derivatives purified by prepara-
tive HPLC were isolated by removing the methanol portion of the 
eluent in vacuo, followed by lyophilisation.
General procedure for labelling with [99mTc(OH2)3(CO)3]+
A solution of the bioconjugate 10, 13 or 16 (10−3 or 10−4 M in H2O, 
200 l) was added to a vial with a septum, which was then sealed 
and degassed with a stream of nitrogen gas for 10 min. A solution 
of [99mTc(OH2)3(CO)3]+ (1800 l)28,29 was added to the vial via a 
syringe and the vial was heated to 50 °C for 30 min to yield the 
[99mTc(CO)3] labelled bioconjugates, which was demonstrated by 
HPLC with radioactive detection. For the HPLC analysis of labelled 
10 or 13, the TFA buffer as buffer a) (described above) was used 
with the C8 column. The following program was used: from 0 to 3 
min only the TFA buffer. At 3.1 it jumped to 25% MeOH, which was 
then kept constant for 6 min. At 9 min a jump to 33% MeOH is fol-
lowed by a linear gradient to 100% MeOH from 9.1 min to 20 min. 
For the analysis of labelled 16, the NaOAc buffer (described above) 
was used as buffer a) with the C8 column. The following program 
was used: from 0% to 15% MeOH in 30 min, then the MeOH con-
tent increased to 100% over 10 min.
Synthesis
Compounds 2,16,30 Cbz-NH-CH2CH2OH,31 Boc-NH-CH2CH2I,32 
Trt-NH-CH2CH2OH·HCl,33 Boc-NH-CH2CH2CH2-Br,34 Re(L-
His)(CO)335 and (NEt4)2[ReBr3(CO)3]36 were prepared according to 
methods in the literature.
Trt-NH-CH2CH2CH2OH·HCl. The compound Trt-NH-
CH2CH2CH2OH·HCl was prepared analogously to the method that 
Maltese reported for the preparation of Trt-NH-CH2CH2OH·HCl.33 
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To a solution of 3-aminopropanol (4.0 ml; 3.93 g; 15.7 mmol) 
in MeCN (20 ml) was added chlorotriphenylmethane (2.0 g; 
7.2 mmol). After the mixture was stirred for 30 min at RT, it was 
poured into 200 ml of H2O and stirred for 10 min. During this time a 
white precipitate formed, which was isolated by filtration and dried 
in vacuo. The white solid was dissolved in 60 ml anhydrous diethyl 
ether and gaseous HCl was bubbled through the solution, resulting 
in the formation of a finely divided white precipitate. It was isolated 
by filtration, washed with Et2O and air-dried. Yield: 2.15 g; 85%.
Found: C, 74.7; H, 6.9; N, 3.9; Calc. for C22H24NOCl: C, 74.7; 
H, 6.8; N, 4.0%.
Fmoc-NH-CH2CH2OH and Fmoc-NH-CH2CH2CH2OH. The 
compounds Fmoc-NH-CH2CH2OH and Fmoc-NH-CH2CH2CH2OH 
were prepared according to the method of Jönsson and Undén.37
Fmoc-NH-CH2-CH2OH. Found: C, 72.3; H, 6.3; N, 4.8 Calc. 
for C17H17NO3: C, 72.1; H, 6.1; N, 4.9%; max (KBr)/cm−1 3333s 
NH, 1692vs CO; H (300 MHz; dmso-d6) 7.89 (2H, pseudo-d, 
2 × ArH ), 7.69 (2H, pseudo-d, 2 × ArH ), 7.40 (2H, pseudo-t, 
2 × ArH ), 7.32 (2H, pseudo-t, 2 × ArH ), 7.25 (1H, t, J 5.7, NH ), 
4.65 (1H, t, J 5.7, OH ), 4.29 (2H, d, J 6.3, OCH2CH ), 4.20 (1H, t, J 
6.3, OCH2CH ), 3.38 (2H, q, J 6.0, 2H, HO-CH2-CH2), 3.05 (2H, q, J 
6.0, NH-CH2-CH2); C (75.47 MHz; dmso-d6) 156.5 (CO), 144.1, 
140.9, 127.8, 127.2, 125.4, 120.3 (Ar-C ), 65.4, 60.0, 46.7, 43.0; m/z 
(ESI-pos.; MeOH) 283 [M + H]+, 305 [M + Na]+.
Fmoc-NH-CH2CH2CH2OH. Found: C, 73.0; H, 6.5; N, 4.8; 
Calc. for C18H19NO3: C, 72.7; H, 6.4; N, 4.7%; max (KBr)/cm−1 
3324s NH, 1689vs CO; H (300 MHz; dmso-d6): 7.87 (2H, 
pseudo-d, 2 × ArH ), 7.68 (2H, pseudo-d, 2 × ArH ), 7.40 (2H, 
pseudo-t, 2 × ArH ), 7.32 (2H, pseudo-t, 2H, 2 × ArH ), 7.25 (1H, 
t, J 5.7, NH), 4.42 (1H, t, J 5.4, OH), 4.28 (2H, d, J 6.3, OCH2CH), 
4.21 (1H, t, J 6.3, OCH2CH ), 3.41 (2H, q, J 6.0, HO-CH2-CH2), 
3.04 (2H, q, J 6.6, NH-CH2-CH2), 1.56 (2H, pentet, J 6.6, CH2-
CH2-CH2); H (75.47 MHz; dmso-d6): 156.4 (CO), 144.1, 140.9, 
127.8, 127.2, 125.3, 120.3 (Ar-C ), 65.4, 58.4, 46.8, 37.5, 32.7; m/z 
(ESI-pos.; MeOH) 297 [M + H]+, 319 [M + Na]+.
General synthesis of the iodide derivatives 4, Trt-NH-
CH2CH2I, Trt-NH-CH2CH2CH2I, Fmoc-NH-CH2CH2I and 6
To a solution of triphenylphosphine (786 mg; 3.0 mmol) and imid-
azole (204 mg; 3.0 mmol for the synthesis of 4, Fmoc-NH-CH2CH2I 
and 6; 408 mg; 6.0 mmol for the synthesis of Trt-NH-CH2CH2I and 
Trt-NH-CH2CH2CH2I) in dry CH2Cl2 (50 ml) under N2 was added 
in small portions I2 (837 mg; 3.0 mmol) over a period of 5 min. 
The mixture was stirred for 15 min at RT and subsequently cooled 
to 0 °C. After the corresponding alcohol derivative was added as a 
solid, the suspension was stirred at 0 °C for 15 min and then stirred 
at RT for 1 h. The mixture was filtered to remove a white solid, fol-
lowed by evaporation of the solvent under reduced pressure. After 
purification by column chromatography (silica; hexane/EtOAc 2/1), 
the iodide was isolated in a 75–92% yield as a colourless solid.
4. Yield: 840 mg; 92%. Found: C, 39.6; H, 4.1; N 4.6; Calc. for 
C10H12NO2I: C, 39.4; H, 3.9; N, 4.6%; max (KBr)/cm−1 3304s NH, 
1679vs CO. H (300 MHz; CD3CN) 7.35 (5H, 5 × ArH ), 5.93 (1H, 
br s, NH), 5.06 (2H, s, O-CH2), 3.41 (2H, q, J 6.6, N-CH2-CH2), 
3.24 (2H, t, J 6.6, N-CH2-CH2); H (75.47 MHz; CD3CN): 157.5 
(CO), 138.5 (ArCq), 129.7, 129.2, 129.0 (Ar-CH), 67.2 (O-CH2), 
44.4 (N-CH2), 6.0 (I-CH2); m/z (ESI-pos.; MeOH) 305 [M + H]+, 
327 [M + Na]+.
Trt-NH-CH2CH2I. Yield: 989 mg; 80%.Found: C, 60.0; H, 
5.0; N, 3.4; Calc. for C21H20NI: C, 59.9; H, 5.0; N, 3.5%; max 
(KBr)/cm−1 3301m NH; H (300.08 MHz; dmso-d6) 7.41 (6H, 
pseudo-d, 6 × ArH ), 7.30 (6H, pseudo-t, 6 × ArH ), 7.19 (3H, 
pseudo-t, 6 × ArH ), 3.26 (2H, pseudo-t, HN-CH2), 3.07 (1H, br s, 
NH), 2.29 (2H, t, J 6.5, I-CH2); H (75.47 MHz; dmso-d6) 146.1, 
128.5, 128.0, 126.4 (ArC), 70.2 (Cq), 46.4 (N-CH2), 7.9 (I-CH2); m/z 
(FAB+, NBA) 413.1 [M+], 243.1 [C(C6H5)3+].
Trt-NH-CH2CH2CH2I. Yield: 978 mg; 76%.
Found: C, 60.9; H, 5.2; N, 3.27; Calc. for C21H22NI: C, 60.7; H, 
5.3; N, 3.4%; max (KBr)/cm−1 3297m NH; H (300.08 MHz; dmso-
d6) 7.41 (6H, pseudo-d, 6 × ArH ), 7.28 (6H, pseudo-t, 6 × ArH ), 
7.17 (3H, pseudo-t, 3 × ArH ), 3.34 (2H, q, J 6.0, NH-CH2-CH2), 
2.76 (1H, t, J 7.5, NH ), 2.1–1.9 (overlapping m, 4H, I-CH2-CH2). 
H (75.47 MHz; dmso-d6): 146.3, 129.0, 128.6, 127.8 (ArC ), 70.3 
(Cq), 43.7 (N-CH2), 34.0 (CH2-CH2-CH2) 7.0 (I-CH2); m/z (FAB+; 
NBA): 427.1 [M+], 243.1 [C(C6H5)3+].
Fmoc-NH-CH2CH2I. Yield: 940 mg; 80%.
Found: C, 52.2; H, 4.2; N, 3.58; Calc. for C17H16NO2I: C, 51.9; 
H, 4.10; N, 3.6%; max (KBr)/cm−1 3336m NH, 1690s CO. H 
(300.08 MHz; CD3CN): 7.83 (2H, pseudo-d, 2 × ArH ), 7.65 (2H, 
pseudo-d, 2 × ArH ), 7.41 (2H, pseudo-t, 2 × ArH ), 7.33 (2H, 
pseudo-t, 2 × ArH ), 5.96 (1H, br s, NH) 4.33 (2H, d, J 6.3, O-CH2), 
4.23 (1H, t, J 6.9, O-CH2-CH ), 3.39 (2H, q, J 6.3, HN-CH2-CH2), 
3.23 (2H, t, J 6.3, I-CH2); H (75.47 MHz; dmso-d6): 156.2 (CO), 
144.0, 140.9, 127.8, 127.3, 125.3, 120.3 (ArC ), 65.5 (CH-FMoc), 
46.7, 43.0 (N-CH2, CH2-FMoc), 6.0 (I-CH2); m/z (ESI-pos., MeOH) 
179, 216, 393 [M + H]+, 415 [M + Na]+.
6. Yield: 1036 mg; 85%. Found: C: 53.2; H, 4.5; N, 3.5; Calc. 
for C18H18NO2I: C, 53.0; H, 4.5; N, 3.4%; max (KBr)/cm−1 3336m 
NH, 1690s CO; H (dmso-d6; 300.08 MHz) 7.86 (2H, pseudo-d, 
2 × ArH ), 7.66 (2H, pseudo-d, 2 × ArH ), 7.42–7.49 (4H, overlap-
ping-m, 4 × ArH ), 4.30 (2H, d, J 6.6, CH2-Fmoc), 4.19 (1H, t, J 
6.6, CH ), 3.19 (2H, t, J 6.9, CH2-I), 3.02 (2H, m, NCH2), 1.87 (2H, 
m, CH2-CH2-CH2), NH not detected; H (dmso-d6; 75.47 MHz) 
156.4 (CO), 144.1, 140.9 (2 × ArCq), 127.8, 127.2, 125.3, 120.3 
(4 × ArCH), 65.3 (CH-Fmoc), 46.8 (CH2-Fmoc), 40.8, 33.2, 
4.9 (CH2); m/z (ESI-pos., MeOH) 179, 230, 407 [M + H]+, 430 
[M + Na]+.
3-(1-Benzyl-1H-imidazol-4-yl)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid methyl ester (5)
A mixture of 2 (196 mg; 1.0 mmol) and 4 (610 mg; 2.0 mmol) in 
MeCN (40 ml) was heated at reflux for 16 h under an atmosphere 
of N2. TLC showed that the starting urea derivative had completely 
reacted. The mixture was concentrated in vacuo, resulting in a white 
solid. This solid was washed with dry Et2O (3 × 20 ml) to remove 
excess 4. The solid material was redissolved in MeCN (40 ml) 
and 9-fluorenylmethanol (588 mg; 3.0 mmol) and dipea (581 mg; 
4.5 mmol) were added. The resulting mixture was stirred at RT 
under N2 for 16 h. The solvent was removed in vacuo, followed by 
purification by column chromatography (silica; CH2Cl2/MeOH 2/1). 
Yield: 274 mg (19% over two steps) of a foamy colourless solid. 
max (KBr)/cm−1 3426s NH, 1746s, 1722vs CO. H (300.08 MHz; 
CD3CN): 7.83 (2H, pseudo-d, 2 × ArH ), 7.62 (2H, pseudo-d, 
2 × ArH ), 7.51 (1H, s, N2CHHis), 7.41 (2H, pseudo-t, 2 × ArH ), 
7.32 (5H, m, 5 × ArH ), 7.17 (2H, pseudo-d, 2 × ArH ), 6.78 (s, 1H, 
CHimidazole), 6.67 (1H, d, J 8.1 Hz, NH), 5.06 (2H, s, N-CH2), 4.34 
(3H, overlapping m, CH + O-CH2), 4.21 (1H, t, J 6.6, O-CH2CH ), 
3.56 (3H, s, OCH3), 2.91 (2H, pseudo-d, CH2). C (75.47 MHz; 
CD3CN) 173.6 (COester), 157.4 (COamide), 145.4, 142.4, 138.9, 
138.7, 138.6, 130.1, 129.2, 129.0, 128.6, 128.4, 126.4, 121.3, 118.4 
(13 × ArC ), 67.4, 55.5, 52.8, 51.2, 48.1 (N-CH2, OCH3, O-CH2-
CH, CH), 30.6 (C); m/z (ESI-pos.; MeOH): 481.9 ([M + H]+, 
C29H28N3O4 requires 482.2 g mol−1).
99Tc(His-N-benzyl)(CO)3
A solution of 40.4 mg (0.084 mmol) 5 was dissolved in CH2Cl2 
(2 ml) and TFA (1.5 ml) was added. The mixture was stirred for 
1.5 h followed by removal of the solvent in vacuo. The residue was 
dissolved in H2O (2 ml) and (NEt4)2[TcBr3(CO)3] was added. The 
pH was adjusted to 7 by carefull addition of a 1 M NaOH solution. 
The mixture was allowed to stir overnight, during which time a 
white/creamy precipitate formed. The solid was isolated by filtra-
tion, washed with H2O and air dried. Yield: 26 mg (72%). HPLC 
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with radiodetection showed one single peak. Crystals suitable for 
X-ray diffraction were grown by slow evaporation of a 1/1 EtOH/
H2O mixture.
3-{1-[3-(9H-Fluoren-9-ylmethoxycarbonylamino)-propyl]-
1H-imidazol-4-yl}-2-(3-trimethylsilanyl-ethylcarboxyamino)-
propionic acid methyl ester (7)
A mixture of 2 (196 mg; 1.0 mmol) and 8b (1.22 g; 3.0 mmol) in 
MeCN (40 ml) was heated at reflux for 4.5 days under an atmo-
sphere of N2. TLC showed that the starting urea derivative had 
completely reacted. The mixture was concentrated in vacuo, result-
ing in a white solid. The solid material was redissolved in MeCN 
(40 ml) and 2-trimethylsilylethanol (355 mg; 3.0 mmol) and dipea 
(259 mg; 2.0 mmol) were added. The resulting mixture was stirred 
at RT under N2 for 16 h. The solvent was removed in vacuo, fol-
lowed by purification by column chromatography (silica; EtOAc). 
Yield: 316 mg (53% over two steps) of a foamy colourless solid
Found: C, 62.1; H, 6.2; N, 9.5; Calc. for C31H40N4O6Si: C, 
62.8; H, 6.8; N 9.5%; max (KBr)/cm−1 3329br NH, 1730s, 1698vs 
CO; H (300.8 MHz; CD3CN) 7.82 (2H, pseudo-d, 2 × ArH ), 
7.64 (2H, pseudo-d, 2 × ArH ), 7.38 (3H, m, 2 × ArH + N2CHHis), 
7.32 (2H, pseudo-t, 2 × ArH ), 6.79 (1H, s, CHHis), 6.55 (1H, d, J 
7.5, NH), 5.68 (1H, br s, NH), 4.35 (3H, overlapping m, OCH2-
Fmoc + CH ), 4.22 (1H, t, J 6.6, OCH2CH-Fmoc), 4.07 (2H, m, 
CH2), 3.87 (2H, m, CH2), 3.60 (3H, s, OCH3), 2.99 (2H, m, CH2), 
2.90 (2H, m, CH2), 1.85 (2H, m, CH2), 0.93 (2H, m, CH2), 0.01 (s, 
9H, Si-(CH3)3). C (CD3CN; 75.47 MHz) 173.7 (COester), 157.7, 
157.6 (2 × COamide), 145.5, 142.2 (2 × ArCq), 138.4 (CHis), 128.9, 
128.3 (2 × ArCH), 126.4 (CHis), 121.2, 118.6 (2 × ArCH), 118.1 
(CHis), 66.9, 63.7, 55.3, 52.7, 48.3, 44.9, 38.6, 32.1, 30.1, 18.3, 1.4 
(Si(CH3)3); m/z (ESI-pos., MeOH) 343, 371, 533, 593 [M + H]+.
3-[1-(3-Amino-propyl)-1H-imidazol-4-yl]-2-(3-
trimethylsilanyl-ethylcarboxyamino)-propionic acid methyl 
ester (8)
Compound 7 (255 mg; 0.43 mmol) was dissolved in a 1/1 DMF/
NEt2 mixture (8 ml). After the mixture was stirred for 1 h at RT, the 
solvent was removed in vacuo. Purification by preperative HPLC 
(C-18ec column; TFA buffer) afforded 8 as a colourless foamy solid 
as its trifluoroacetate salt. Yield: 190 mg (91%).
H (300.08 MHz; CD3CN) 8.59 (1H, s, N2CHHis), 7.95 (3H, br, 
NH3+), 7.26 (1H, s, CHHis), 6.56 (1H, d, J 8.4 Hz, NH), 4.43 (1H, 
m, CH ), 4.24 (2H, t, J 6.9 Hz, CH2), 4.05 (2H, m, CH2), 3.68 (3H, 
s, OCH3), 3.22 (1H, m, CH), 3.06 (1H, m, CH), 2.95 (2H, t, J 
6.9, CH2), 2.21 (2H, m, CH2), 0.89 (2H, m, CH2), 0.00 (9H, s, Si-
(CH3)3); C (75.47 MHz; CD3CN): 172.7 (COester), 162.2 (q, JC, F 
34.6, CF3), 157.7 (COamide), 135.9, 132.4, 120.7 (3 × CHis), 64.0, 
54.6, 53.2, 47.0, 37.3, 28.6, 27.6, 18.2 (OCH3, C, C + 5 × CH2), 
1.5 (Si-(CH3)3); m/z (ESI-pos.; MeOH): 343.1, 370.8 ([M + H]+, 
C16H30N4O4Si requires 371.2) 762 [2M + Na]+.
Biotin conjugate 9
D-(+)-Biotin (35 mg; 0.14 mmol) was dissolved in a 4/1 (v/v) mix-
ture of DMF/NEt3 (2.5 ml). To this mixture a solution of 8 (91 mg; 
0.19 mmol) was added in DMF (2 ml), followed by addition of 
TBTU (46 mg; 0.14 mmol). After stirring for 45 min at RT, it was 
evaporated to dryness in vacuo. The residue was taken up in 2 M 
NaHCO3 (20 ml) and extracted with CH2Cl2 (3 × 20 ml). The com-
bined organic layers were washed with 0.5 M HCl (20 ml), H2O 
(20 ml) and brine (2 × 20 ml). After removal of the solvent, 9 was 
obtained as a colourless foamy solid. Yield: 67 mg (78%; relative 
to biotin).
H (300.08 MHz; CD3OD) 7.60 (1H, s, N2CHHis), 6.95 (1H, 
s, CHHis), 4.48 (1H, m), 4.41 (1H, m), 4.29 (1H, m), 4.09 (2H, 
m), 3.98 (2H, m), 3.69 (3H, s, OCH3), 3.16 (3H, overlapping-m, 
CH2 + H ), 2.95–2.78 (5H, overlapping-m, 2 × CH2 + H), 2.70 (1H, 
m), 2.19 (2H, m, CH2), 1.93 (2H, m, CH2), 1.63 (4H, m, 2 × CH2), 
1.43 (2H, m, CH2), 0.94 (2H, m, CH2), 0.01 (9H, s, Si-(CH3)3; C 
(75.47 MHz; CD3OD): 176.4, 174.3 (COester + N2CO), 166.3, 
158.9 (COamide), 138.5, 138.3, 118.7 (ArCHis), 64.2, 64.4, 61.7, 
57.1, 55.7, 52.8, 45.7, 41.1, 37.4, 36.8, 31.9, 31.1, 29.8, 29.5, 26.8, 
18.6 (10 × CH2, C, C, OCH3, 3 × CH), 1.5 (Si-(CH3)3; m/z (FAB+; 
NBA) 597.2898 (M+, C26H45N6O6SiS requires 597.2891).
Biotin conjugate 10
To a solution of 9 (100 mg; 0.17 mmol) in DMF (5 ml) was added 
1 ml of a 1 M NBu4F solution in THF. After heating the mixture at 
70 °C for 1.5 h, the solvent was removed in vacuo. Purification by 
preparative HPLC (C18ec column; TFA gradient) afforded 72 mg 
(79%) of the trifluoro acetate salt of 10 as a colorless foamy solid.
H (500.25 MHz; CD3OD): 8.94 (1H, s, N2CHHis), 7.54 (1H, s, 
CHHis), 4.50 (1H, m), 4.30 (2H, m), 4.22 (2H, t, J 6.6, N-CH2), 3.45 
(1H, m), 3.33 (1H, m), 3.20 (3H, m), 2.91 (1H, dd, 3J 4.9, 2J 12.6, 
CH ), 2.67 (1H, d, 2J 12.6, CH ), 2.24 (2H, t, J 7.3, OC-NH-
CH2), 2.07 (2H, m, CH2CH2CH2), 1.66 (4H, m), 1.45 (2H, m). C 
(125.8 MHz; MeOH-d4) 176.7, 179.6, 166.3 (3 × CO), 162.9 (q, 
JC, F 36, CF3COO), 137.2 (ArCHHis), 129.4 (ArCHis), 122.5 (ArCHHis), 
119.3 (q, JC, F 292, CF3), 63.6, 61.8, 57.2, 53.2 (4 × CH), 48.3, 41.2, 
36.8, 36.8, 31.3, 29.9, 29.6, 26.9, 26.9 (9 × CH2); m/z (FAB+; NBA) 
439.2151 ([M + H]+, C19H31N6O4S requires 439.2127).
Boc-(Tyr-tBu)-Gly-Gly-Phe-Leu-OH (11)
The synthesis of Boc-Tyr(tBu)-Gly-Gly-Phe-Leu-OH was per-
formed via solid phase peptide synthesis methods, adapting 
the Fmoc strategy. The H-Leu-2-ClTrt resin was obtained from 
Advanced ChemTech and had a loading of 1.3 mmol g−1 with 
a mesh-size of 100–200. All coupling reagents and amino acids 
were purchased from Novabiochem and used without further 
purification.
Coupling reactions were performed with 5 equivalents of amino 
acid and HOBt and 4.9 equivalents of TBTU for 30 min in DMF. 
Deprotection was performed twice for 5 min using 20% piperidine 
in DMF. After complete assembly, the product was cleaved from the 
resin by 1% TFA in DCM, containing 3% of triisopropylsilane as 
a scavenger. After evaporating the solvents the crude product was 
repeatedly washed with cold ether and subsequently lyophilised.
H (500.25 MHz; CD3OD): 7.26 (4H, m, 4 × ArHPhe), 7.18 (1H, 
m, ArHPhe), 7.10 (2H, pseudo-d, 2 × ArHTyr), 6.89 (2H, pseudo-d, 
2 × ArHTyr), 4.68 (1H, m, CH ), 4.43 (1H, m, CH ), 4.25 (1H, m, 
CH ), 3.88 (2H, m, CH2), 3.72 (2H, m, CH2), 3.18 (1H, m, CH ), 
3.10 (1H, m, CH ), 2.92 (1H, m, CH ), 2.81 (1H, m,CH ), 1.71 
(1H, m, CHLeu), 1.63 (2H, m, CH2-Leu), 1.35 (9H, s, Tyr-OC(CH3)3), 
1.29 (9H, s, Boc-(CH3)3), 0.94 (3H, d, J 6.4, Leu-CH3), 0.90 (3H, 
d, J 6.4, Leu-CH3); C (125.8 MHz; CD3OD;) 175.8, 175.3, 173.6, 
172.3, 171.3, 158.2 (5 × CO), 155.4, 138.6, 133.9, 131.8, 130.6, 
129.6, 127.9, 125.4 (10 × ArC ), 81.0, 79.7 (2 × C(CH3)3), 58.1, 
56.0, 52.3, 44.0, 43.5, 41.8, 39.0, 38.4 (CH and/or CH2), 29.4, 29.0 
(2 × C(CH3)3), 26.1, 23.7, 22.1; m/z (FAB+; NBA): 734.2 ([M + H]+, 
C37H53NaN5O9 requires 734.4).
Enkephalin conjugate 12
To a solution of purified 8 (39 mg; 0.08 mmol) and 11 (85 mg; 
0.08 mmol) in DMF (1.5 ml) and NEt3 (0.5 ml) was added TBTU 
(25 mg; 0.08 mmol). The mixture was stirred for 45 min at RT and 
concentrated to dryness in vacuo. The compound was purified by 
two consequetive HPLC runs (run 1: C8-column; 50 mM TRIS 
buffer; run 2: C8-column; TFA buffer). Yield: 42 mg (49%) of a 
glassy solid.
H (500.25 MHz; CD3OD) 8.77 (1H, s, N2CHHis), 7.43 (1H, s, 
CHHis), 7.28 (4H, m, 4 × ArH ), 7.20 (1H, m, ArH ), 7.12 (2H, pseudo-
d, 2 × ArH ), 6.90 (2H, pseudo-d, 2 × ArH ), 4.52 (1H, m, CH), 4.49 
(1H, m, CH), 4.22–4.09 (7H, overlapping m, 2 × CH + 2 × CH2), 
3.85 (2H, m, CH2-Gly), 3.78 (2H, m, CH2-Gly), 3.73 (3H, s, OCH3), 
3.25–3.02 (9H, overlapping m, 2 × CH2 + 3 × CH), 2.84 (1H, m, 
CH), 2.04 (1H, m, CH2-CH2-CH2), 1.71 (1H, m, CH-Leu), 1.56 
(2H, m, CH2), 1.36 (9H, s, OC(CH3)3), 1.28 (9H, s, OC(CH3)3), 
0.94 (3H, d, J 6.3, Leu-CH3), 0.89 (3H, d, J 6.3, Leu-CH3); C 
(90.5 MHz; CD3OD) 175.5, 175.1, 174.2 172.9, 172.6, 158.7, 158.2 
2 6 0 2 O r g .  B i o m o l .  C h e m . ,  2 0 0 4 ,  2 ,  2 5 9 3 – 2 6 0 3 O r g .  B i o m o l .  C h e m . ,  2 0 0 4 ,  2 ,  2 5 9 3 – 2 6 0 3 2 6 0 3
(CO, 7 signals detected whereas 8 are expected, probably two 
signals overlap), 155.4, 138.3, 136.4, 133.6, 130.9, 130.2, 129.6, 
128.0, 125.2, 121.2 (all ArC ), 81.0, 79.6 (Cq), 64.5, 58.0, 57.5, 
54.4, 53.2, 47.6, 44.1, 41.0, 38.1, 38.0, 36.3, 30.8, 29.2, 28.7, 28.2, 
25.9, 23.5, 21.7, 18.6, −1.5 (CH, CH2 and CH3; 20 signals detected 
whereas 21 are expected. Possibly two signals overlap or a signal 
is obscured by the MeOH signal); m/z (FAB+; NBA)1064.5789 
([M + H]+, C53H82N9O12Si requires 1064.5852).
Enkephalin conjugate 13
Compound 12 (42 mg; 0.04 mmol) was dissolved in 3 ml of a mix-
ture of CH2Cl2/TFA (1/1 v/v). After the mixture was stirred at RT 
for 2 h, it was concentrated to dryness in vacuo. Purification by pre-
parative HPLC (C18ec-column; TFA buffer) afforded 29 mg (88%) 
of the trifluoroacetate salt of 13 as a colourless solid.
H (500.25 MHz; CD3OD) 8.91 (1H, s, N2CHHis), 7.54 (1H, s, 
CHHis), 7.27 (4H, m, 4 × ArCHPhe), 7.21 (1H, m, ArCHPhe), 7.10 (2H, 
pseudo-d, 2 × ArCHTyr), 6.76 (2H, pseudo-d, 2 × ArCHTyr), 4.53 
(1H, m, CH ), 4.45 (1H, m, CH ), 4.21 (3H, m, CH + N-CH2), 
4.08 (1H, m, CH ), 3.93 (2H, m, CH2-Gly), 3.85 (3H, s, OCH3), 
3.79 (2H, m, CH2-Gly), 3.15 (4H, overlapping m, CH2 + NH-
CH2), 2.99 (2H, m, CH2), 2.07 (2H, m, N-CH2-CH2), 1.67 (1H, m, 
CHLeu), 1.58 (2H, m, CH2), 0.91 (3H, d, J 6.2, Leu-CH3), 0.89 (3H, 
d, J 6.2, Leu-CH3); C (125.8 MHz; CD3OD) 175.3, 174.3, 172.5, 
172.1, 170.9, 169.6 (6 × CO), 163.0 (q, JC, F 35, CF3COOH), 
158.5, 138.3, 137.5, 131.8, 130.4, 129.3, 129.8, 128.2, 126.2, 
122.7, 117.0 (All ArC ), 57.4, 56.3, 54.3, 54.3, 53.2, 47.8, 43.8, 
43.7, 41.2, 38.7, 37.9, 36.5, 30.8, 27.9, 26.9, 24.2, 21.9; m/z (FAB+; 
NBA) = 764.4128 ([M + H]+, C38H54N9O8 requires764.4095).
Vitamin B12-b-acid; cyanocobalamin b-monocarboxylic acid 
(14)
Vitamin B12 (1.88 g, 1.39 mmol) was hydrolyzed in HCl 0.1 M 
(190 ml) as described in the literature.25–27 The purification was 
modified in the following way: the Dowex column allowed, after 
desalting by phenol extractions, the isolation of three fractions, 
one containing exclusively d-acid, a second one consisting of a 
mixture of b-acid and d-acid, and a third fraction consisting of a 
mixture of b-acid and e-acid. The mixture of b-acid and d-acid was 
separated by preparative HPLC (column: Waters XTerra Prep RP8, 
5 m, 30 × 100 mm; buffer a: acetate buffer; gradient: 0.5% min−1 
starting from 100% buffer a). The mixture of b-acid and e-acid was 
separated analogously but using the Tris buffer as buffer a. Cyano-
cobalamin-b-acid was isolated in a yield of 280 mg (15%).
C (125.80 MHz; CD3OD): 181.8, 180.2, 177.6, 176.8, 176.7, 
175.7, 175.6, 175.5, 174.7, 174.4, 174.3, 167.2, 166.9, 143.5, 138.3, 
135.7, 134.0, 131.5, 118.3, 112.6, 108.8, 105.2, 95.7, 88.0, 86.5, 
83.7 (d, JC, P 5.7), 76.4, 75.5, 73.7 (d, JC, P 5.8), 62.8, 62.1, 61.1, 60.5, 
57.6, 56.9, 55.1, 52.6, 49.9, 46.8, 43.9, 43.3, 40.2, 35.6, 35.4, 33.5, 
33.1, 33.0, 32.5, 32.4, 29.7, 27.5, 27.1, 21.0, 20.6, 20.4, 20.3 (d, JC, P 
2.7), 20.0, 17.7, 17.2, 16.6, 16.2. P (202.5 MHz; CD3OD)1.24.
Vitamin B12-b-acid conjugate 15
Compound 7 (44 mg; 0.07 mmol) was dissolved in DMF (1.5 ml) 
and Et2N (1.5 ml). The mixture was stirred for 1 h at RT. Subse-
quently the mixture was evaporated to dryness in vacuo. In another 
flask, 14 (20.0 mg, 14.8 mol) was dissolved in 4.5 ml of a DMSO/
DMF (1/5 v/v) mixture. This mixture was transferred to the flask 
containing the deprotected histidine derivative. Subsequently NEt3 
(1.0 ml) and TBTU (32.1 mg; 0.1 mmol) were added. The mixture 
was stirred for 45 min at RT, after which period it was concentrated 
to dryness in vacuo. Purification by preparative HPLC (C8-column; 
acetate buffer; gradient: 2.0% per min, starting from buffer a) af-
forded 16 mg (67%) of a red solid.
C (125.80 MHz; CD3OD) 181.7, 180.3, 177.8, 177.7, 176.8, 
175.8, 175.7, 175.5, 174.8, 174.8, 174.4, 174.2, 167.3, 167.1, 158.8, 
143.7, 138.6, 138.5, 138.4, 135.8, 133.9, 131.7, 118.6, 118.0, 116.9, 
112.7, 108.9, 105.3, 95.8, 88.1, 86.6, 83.9 (d, JC, P 5.9), 76.5, 75.7, 
73.7 (d, JC, P 5.9), 70.9, 64.4, 62.9, 60.5, 57.7, 57.2, 55.8, 55.3, 52.9, 
52.7, 50.0, 48.6, 47.0, 45.7, 44.1, 43.1, 40.3, 37.7, 36.7, 35.5, 33.6, 
33.2, 33.1, 32.5, 32.5, 32.1, 31.4, 29.8, 27.6, 27.5, 21.1, 20.7, 20.5, 
20.5, 20.4 (d, JC, P 2.6), 18.8, 17.7, 17.3, 16.6, 16.3, −1.3 (Si-(CH3)3); 
P (202.5 MHz; CD3OD)1.24; m/z (MeOH; ESI-pos.): 1710.4 
([M + H]+, C79H115CoN17O18PSi requires 1709.9), 855.0 [M + 2H]2+, 
866.7 [M + Na + H]2+.
Vitamin B12-b-acid conjugate 16
To a suspension of 15 (19 mg; 11.1 mol) in CH2Cl2 (4 ml) at 0 °C 
under an atmosphere of N2 was added CF3COOH (1 ml), result-
ing in a clear red solution. The mixture was stirred for 4 h at 0 °C 
followed by evaporation of the solvent in vacuo. Purification by 
preparative HPLC (RP8 30 × 100 mm column; acetate buffer; gra-
dient: 1.0% per min, starting from buffer a), yielded 11 mg (64%) 
of a red solid.
C (CD3OD; 125.8 MHz): 181.7, 180.3, 177.7, 177.7, 176.7, 
175.7, 175.6, 175.5, 175.5, 174.8, 174.8, 174.3, 167.3, 167.0, 143.6, 
138.8, 138.4, 138.2, 135.7, 133.9, 131.6, 118.9, 118.0, 112.7, 108.8, 
105.3, 95.8, 88.1, 86.5, 83.8 (d, JC, P 5.6), 76.5, 75.6, 73.7 (d, JC, P 
6.1), 70.9, 62.8, 60.5, 57.6, 57.1, 55.3, 55.2, 52.8, 52.7, 50.0, 46.9, 
45.7, 44.0, 43.1, 40.3, 37.7, 36.7, 35.5, 33.6, 33.6, 33.1, 32.5, 32.5, 
32.0, 29.8, 27.5, 27.5, 21.1, 20.7, 20.5, 20.3, 20.1, 17.7, 17.2, 16.5, 
16.2; P (202.5 MHz; CD3OD)1.24; m/z (ESI-pos.; MeOH): 1565.2 
([M + H]+, C73H104CoN17O16P requires 1565.6), 1587.2 [M + Na]+, 
783.4 [M + 2H]2+, 794.1 [M + Na + H]2+.
Re complex 17
To a solution of Re(His)(CO)3 (178 mg; 0.4 mmol) and Boc-NH-
CH2CH2CH2Br (100 mg; 0.4 mmol) in DMF (4 ml) was added 
Cs2CO3 (140 mg; 0.4 mmol). The resulting suspension was heated 
at 40 °C for 16 h. After the solvent was removed in vacuo, the resi-
due was taken up in CH2Cl2 (25 ml) and H2O (20 ml). The phases 
were separated and the aqueous solution was extracted with CH2Cl2 
(25 ml). The CH2Cl2 were combined and washed with brine (2 × 
20 ml) and dried (MgSO4). Yield: 230 mg (97%) of a colourless 
solid.
Found: C, 35.4; H, 3.9; N, 9.8. Calcd. for C17H23N4O7Re: C, 
35.1; H, 4.0; N, 9.6%; max (KBr)/cm−1 3436m NH, 2020s, 1894s, 
CO; C (500.25 MHz; CD3CN): 7.94 (1H, s, N2CHHis), 6.92 (1H, 
s, CHHis), 5.45 (1H, br, NH-Boc), 4.61 (1H, m, CH ) 3.96 (2H, t, 
J 7.0, N-CH2), 3.88 (1H, m, Re-NH ), 3.83 (1H, m, Re-NH ), 3.20 
(1H, m, CH ), 2.99 (3H, m, CH + Boc-NH-CH2), 1.87 (2H, m, 
CH2-CH2-CH2), 1.40 (9H, s, OC(CH3)3). C (75.47 MHz; CD3CN): 
199.5 (CO), 197.9 (2 × CO), 182.8 (His-CO2), 163.8 (Boc-CO), 
142.5, 135.8, 119.7 (ArCHis), 79.5 (Cq-Boc), 52.6, 46.2, 38.0, 31.7, 
28.8 (3 × CH2 + C + C) 28.6 (Boc-CH3); m/z (ESI-pos.; MeOH) 
483 [M − Boc + 2H]+, 527 [M − C4H9 + 2H]+, 582 [M + H]+, 605 
[M + Na]+, 1165 [2M + H]+, 1187 [2M + Na]+.
Biotin conjugate 18
To a solution of complex 17 (98 mg; 0.17 mmol) in CH2Cl2 (4 ml) 
at 0 °C was added TFA (2 ml). The mixture was stirred for 1 h at 
0 °C, followed by removal of the solvent in vacuo. In a separate 
flask D-(+)-biotin (41 mg; 0.17 mmol) was dissolved in a 4/1 (v/v) 
DMF/NEt2 solution. This mixture was added to the Re complex and 
TBTU (55 mg; 0.17 mmol) was added. After it had been stirred at 
RT for 45 min, the mixture was evaporated to dryness in vacuo. The 
sticky residue was washed with EtOAc (2 × 50 ml) and H2O (2 × 
10 ml to remove some side-products. The residue was dissolved in 
a minimum amount of MeOH and subsequently purified by column 
chromatography (EtOH). Yield: 47 mg (40%) of a white colourless 
solid.
max (KBr)/cm−1 3309w NH, 2019vs CO, 1884vs br, CO, 1687s, 
1636s, CO; H (500.25 MHz; CD3OD) 8.09 (1H, s, N2CHHis), 
6.92 (1H, s, CHHis), 5.73 (1H, m, Re-NH ), 5.09 (1H, Re-NH ), 4.48 
(1H, m), 4.29 (1H, m), 4.02 (3H, overlapping m, CH + N-CH2), 
3.17 (5H, overlapping m, CH2 + CH-biotin + CH2-biotin), 2.90 
(1H, dd, J 5.0, 2J 12.8, S-CH ), 2.71 (1H, d, J 12.8 Hz, S-CH ), 
2.20 (2H, J 7.3 Hz, biotin-CH2), 1.94 (2H, m, N-CH2-CH2), 
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1.62 (4H, overlapping m, 2 × CH2), 1.42 (2H, m, biotin CH2); C 
(125.80 MHz; CD3OD): 198.9, 197.7, 197.4 (3 × CO), 185.3, 176.5, 
166.3 (3 × CO), 142.9, 136.1, 120.1 (ArCHis), 63.5, 61.8, 57.2, 
53.5, 46.7, 41.2, 37.4, 36.9, 31.8, 29.9, 29.6, 29.0, 26.9; m/z (FAB+; 
NBA): 707.1434 (M+, C22H30N6O7185ReS requires 707.1429), 
709.1522 (M+, C22H30N6O7187ReS requires 709.1454).
Vitamin B12-b-acid conjugate 19
To a solution of complex 17 (40 mg; 0.07 mmol) in CH2Cl2 (2 ml) at 
0 °C was added TFA (1 ml). The mixture was stirred for 1 h at 0 °C, 
followed by removal of the volatiles in vacuo. In a different flask 
14 (20.0 mg, 14.8 mol), was dissolved in DMSO (0.8 ml). Sub-
sequently were added DMF (2 ml) and NEt3 (0.1 ml). The mixture 
was transferred to the flask containing the Re complex and TBTU 
(32.1 mg; 0.1 mmol) was added. After stirring at RT for 45 min, the 
solvent was removed in vacuo. The residue was purified by pre-
parative HPLC (acetate system, gradient: 2.0% min−1 starting from 
100% buffer a) to afford 7 mg (26%) of 19.
max (KBr)/cm−1 2020s, 1901vs br CO, 1664vs br CO.
C (125.8 MHz; CD3OD) 199.0, 197.6, 197.3 (3 × CO), 185.3, 
181.7, 180.3, 177.7, 176.8, 175.7, 175.7, 175.1, 174.9, 174.8, 174.4, 
167.3, 167.1, 143.6, 143.1, 138.4, 136.2, 135.8, 133,9, 131.6, 120.1, 
118.0, 112.7, 108.9, 105.3, 95.8, 88.1, 86.6, 83.9, 76.5, 75.7, 73.8, 
70.9, 62.8, 60.5, 83.8, 76.5, 75.7, 73.8, 57.6, 57.1, 55.2, 53.4, 53.3, 
52.7, 50.0, 46.7, 46.6, 44,1, 43.2, 40.3, 37.5, 36.6, 35.5, 33.6, 33.1, 
32.5, 29.8, 28.9, 27.6, 27.4, 21.1, 20.6, 20.5, 20.3, 20.1, 17.7, 17.2, 
16.5, 16.2; P (202.5 MHz; CD3OD): 1.25; m/z (ESI-pos.; MeOH): 
911.6 [M + 2H]2+, 923.2 [M + H + Na]2+, 933.9 [M + 2Na]2+, 
1822.1 ([M + H]+, C75H101CoN17O19PRe requires 1820.6), 1845.6 
[M + Na]+.
X-Ray crystal structure determination of 99Tc(His-N-
benzyl)(CO)3·H2O
Crystal data. C16H16N3O6Tc, M = 957.12, orthorhombic, a = 
9.0094(5), b = 13.0282(7), c = 15.5661(12) Å, V = 1827.1(2) Å3, 
T = 183(2) K, space group P212121, Z = 4, (Mo-K) = 0.825 mm−1, 
28804 reflections measured, 4425 unique (Rint = 0.0502) which were 
used in all calculations. The final R1 was 0.0501 and the final wR(F 2) 
was 0.0915 (all data). The Flack parameter was −0.03(5), in good 
agreement with the known stereochemistry (L) of the histidine.
CCDC reference number 236282. See http://www.rsc.org/
suppdata/ob/b4/b405575f/ for crystallographic data in .cif or other 
electronic format.
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